Trial Profile
A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Superficial Bladder Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Nadofaragene-firadenovec (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors FKD Therapies
- 27 Jan 2024 Primary endpoint (Incidence of High Grade-Recurrence Free Survival at 360 Days) has been met, as per results presented at the 2024 Genitourinary Cancers Symposium.
- 27 Jan 2024 Results assessing the utility of uMRD to identify molecular response to Nadofaragene in patients with high-grade BCG-refractory or relapsed NMIBC, presented at the 2024 Genitourinary Cancers Symposium.
- 24 Aug 2017 Results published in The Society of Urologic Oncology and the Society of Urologic Oncology Clinical Trials Consortium media release.